JP2024540226A5 - - Google Patents
Info
- Publication number
- JP2024540226A5 JP2024540226A5 JP2024525880A JP2024525880A JP2024540226A5 JP 2024540226 A5 JP2024540226 A5 JP 2024540226A5 JP 2024525880 A JP2024525880 A JP 2024525880A JP 2024525880 A JP2024525880 A JP 2024525880A JP 2024540226 A5 JP2024540226 A5 JP 2024540226A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- seq
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275045P | 2021-11-03 | 2021-11-03 | |
| US63/275,045 | 2021-11-03 | ||
| US202163290278P | 2021-12-16 | 2021-12-16 | |
| US63/290,278 | 2021-12-16 | ||
| US202263316616P | 2022-03-04 | 2022-03-04 | |
| US202263316582P | 2022-03-04 | 2022-03-04 | |
| US63/316,582 | 2022-03-04 | ||
| US63/316,616 | 2022-03-04 | ||
| PCT/IB2022/060604 WO2023079485A1 (en) | 2021-11-03 | 2022-11-03 | Anti-tau antibody compositions, dosage forms, and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540226A JP2024540226A (ja) | 2024-10-31 |
| JP2024540226A5 true JP2024540226A5 (enExample) | 2025-12-01 |
Family
ID=84360026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525880A Pending JP2024540226A (ja) | 2021-11-03 | 2022-11-03 | 抗タウ抗体組成物、投薬形態、及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4426336A1 (enExample) |
| JP (1) | JP2024540226A (enExample) |
| KR (1) | KR20240118915A (enExample) |
| AU (1) | AU2022381556A1 (enExample) |
| CA (1) | CA3237660A1 (enExample) |
| MX (1) | MX2024005430A (enExample) |
| TW (1) | TW202334201A (enExample) |
| WO (1) | WO2023079485A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025137359A1 (en) | 2023-12-20 | 2025-06-26 | Eisai R&D Management Co., Ltd. | Assay methods to identify a disease |
| CN117946264B (zh) * | 2024-03-21 | 2024-06-04 | 江西赛基生物技术有限公司 | 一种抗Tau蛋白单克隆抗体及其应用 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016010454A2 (pt) * | 2013-11-27 | 2017-12-05 | Ipierian Inc | métodos para tratar uma taupatia |
| UA128383C2 (uk) * | 2016-12-07 | 2024-07-03 | Дженентек, Інк. | Антитіло до тау-білка та спосіб його застосування |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| WO2022144406A1 (en) * | 2020-12-29 | 2022-07-07 | Neurimmune Ag | Human anti-tau antibodies |
-
2022
- 2022-11-03 EP EP22805963.0A patent/EP4426336A1/en active Pending
- 2022-11-03 MX MX2024005430A patent/MX2024005430A/es unknown
- 2022-11-03 TW TW111142044A patent/TW202334201A/zh unknown
- 2022-11-03 KR KR1020247018587A patent/KR20240118915A/ko active Pending
- 2022-11-03 AU AU2022381556A patent/AU2022381556A1/en active Pending
- 2022-11-03 JP JP2024525880A patent/JP2024540226A/ja active Pending
- 2022-11-03 WO PCT/IB2022/060604 patent/WO2023079485A1/en not_active Ceased
- 2022-11-03 CA CA3237660A patent/CA3237660A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540226A5 (enExample) | ||
| JP2024531151A5 (enExample) | ||
| JP2023517236A5 (enExample) | ||
| JP2020509027A5 (enExample) | ||
| JP2022515077A5 (enExample) | ||
| JP2018512435A5 (enExample) | ||
| JP2017507954A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| CA2984464C (en) | Treatment for multiple myeloma (mm) | |
| JP2013542194A5 (enExample) | ||
| JP2011506483A5 (enExample) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2022515770A5 (enExample) | ||
| WO2013039954A1 (en) | Anti-gitr antibodies | |
| TW201024310A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine | |
| JP2021527640A5 (enExample) | ||
| JP2021532126A5 (enExample) | ||
| JP2022523372A5 (enExample) | ||
| JP2023545520A5 (enExample) | ||
| JP2024515968A5 (enExample) | ||
| JP2024516698A5 (enExample) | ||
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP2023520771A5 (enExample) | ||
| JP2023546503A5 (enExample) | ||
| JP2023502398A5 (enExample) |